Literature DB >> 647966

Similar behaviour of lecithin:cholesterol acyltransferase and pseudocholinesterase in liver disease and hyperlipoproteinemia.

M Cucuianu, A Opincaru, D Tapalagă.   

Abstract

Using exogenous substrate for its assay, lecithin:cholesterol acyltransferase (LCAT) was found to be decreased in liver disease and higher than normal in endogenous hypertriglyceridemia. LCAT activity was positively correlated with serum cholesterol and triglyceride. However in the six patients with excessive hypertriglyceridemia (type V), LCAT activity was lower than in type IV hyperlipoproteinemia. LCAT activity was not changed significantly in type II-a hyperlipoproteinemia. A striking parallel was noted between plasma LCAT and serum pseudocholinesterase activity. It suggested that both these liver secretion enzymes might be induced by an accelerated turnover of serum lipids and lipoproteins. Pathogenical implications of these findings are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647966     DOI: 10.1016/0009-8981(78)90103-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  A case of familial hyper-cholinesterasemia associated with isozyme variant band.

Authors:  K Yamamoto; F Morito; M Motomura; H Kaneoka; T Sakai
Journal:  Gastroenterol Jpn       Date:  1986-08

2.  Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome.

Authors:  J Tajiri; Y Nishizono; S Fujiyama; K Sagara; T Sato; H Shibata
Journal:  Gastroenterol Jpn       Date:  1983-04

3.  Increased lysolecithin acyltransferase activity in the plasma of type II hyperlipoproteinemic patients.

Authors:  P V Subbaiah; J T Ogilvie
Journal:  Lipids       Date:  1984-02       Impact factor: 1.880

4.  Butyrylcholinesterase as a prognostic marker: a review of the literature.

Authors:  Lidia Santarpia; Ilenia Grandone; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-06       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.